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Abstract  18 
Oxidative stress generates reactive species that modify proteins, deplete antioxidant defenses and contribute to 19 
chronic obstructive pulmonary disease (COPD) and ischemic heart disease (IHD).  To determine whether 20 
protein modifications differ between COPD or IHD patients and healthy subjects, we performed untargeted 21 
analysis of adducts at the Cys34 locus of human serum albumin (HSA).  Biospecimens were obtained from 22 
nonsmoking participants from London, U.K., including healthy subjects (n=20) and patients with COPD (n=20) 23 
or IHD (n=10). Serum samples were digested with trypsin and analyzed by liquid chromatography-high 24 
resolution mass spectrometry.  Effects of air pollution on adduct levels were also investigated based on 25 
estimated residential exposures to PM2.5, O3 and NO2. For the 39 adducts with sufficient data, levels were 26 
essentially identical in blood samples collected from the same subjects on two consecutive days, consistent with 27 
the 28-d residence time of HSA. Multivariate linear regression revealed 21 significant associations, mainly with 28 
the underlying diseases but also with air-pollution exposures (p-value < 0.05). Interestingly, most of the 29 
associations indicated that adduct levels decreased with the presence of disease or increased pollutant 30 
concentrations.  Negative associations of COPD and IHD with the Cys34 disulfide of glutathione and two 31 
Cys34 sulfoxidations, were consistent with previous results from smoking and non-smoking volunteers and 32 
nonsmoking women exposed to indoor combustion of coal and wood.    33 
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 37 
Introduction 38 
Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease, characterized by 39 
persistent air flow limitation, that affects about 170 million people worldwide 1 and is an increasingly important 40 
cause of disability and death 2. Tobacco smoking is a well-established risk factor for COPD as are exposures to 41 
indoor air pollution from combustion of solid fuels, ambient air pollution and some occupational chemicals 3-6. 42 
The incidence of COPD has also been linked to increased risks of ischemic heart disease (IHD), which resulted 43 
in 15.9% of all worldwide deaths in 2015 7.  Risk factors for IHD also include smoking and air pollution, as well 44 
as hypertension, obesity, diabetes, lack of exercise and psychosocial stress 8-9. The causal links between both 45 
COPD & IHD and exposures to cigarette smoke and air pollution involve irritating gases and fine particles (PM2.5) 46 
that trigger oxidative stress with the subsequent cascade of inflammation, carbonyl stress, mitochondrial injury 47 
and altered gene expression 10-11. A common element of this progression is generation of reactive oxygen species 48 
(ROS) and other electrophiles that can modify functional macromolecules and reduce antioxidant defenses. 49 
Despite their importance to disease processes, reactive electrophiles cannot generally be measured in blood 50 
because they have short life spans in vivo.  For this reason, investigators have studied their dispositions by 51 
monitoring modifications to abundant proteins. Our laboratory has developed an untargeted ‘adductomics’ 52 
method to investigate modifications at a highly nucleophilic cysteine residue (Cys34) of human serum albumin 53 
(HSA) 12. We focused on Cys34, not only because it efficiently scavenges small reactive electrophiles 13-14, but 54 
also because its oxidation promotes a host of covalent modifications to circulating thiols 15 that can act as redox 55 
switches in homeostatic processes 16-17.  These Cys34 sulfoxidation products and disulfides represent potential 56 
biomarkers of oxidative stress and the redox state of the serum over the 1-month residence time of HSA (21-d 57 
half-life) 18-19.  58 
We initially characterized adductomes with archived serum/plasma from healthy smokers and nonsmokers and 59 
discovered several adducts that were significantly associated with smoking 12. Some associations had been 60 
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expected, including higher levels of adducts of ethylene oxide, acrylonitrile and methylation in smokers.  61 
However, smoking produced lower levels of three Cys34 sulfoxidations that we had expected to be more abundant 62 
in smokers because of oxidative stress. In a more recent study, we performed Cys34 adductomics with serum 63 
from nonsmoking Chinese women, who were exposed to high levels of indoor pollutants from residential 64 
combustion of coal and wood 20. Interestingly, Cys34 disulfides of the antioxidant glutathione (GSH) and two of 65 
its precursors, i.e. -glutamyl cysteine (-GluCys) and cysteinyl glycine (CysGly), were present at lower 66 
concentrations in subjects exposed to combustion products than in controls. These preliminary studies suggest 67 
that the Cys34 adductome reflects a complex interplay of exposures and redox processes involving reactive 68 
oxygen species and antioxidants and that ‘normal’ levels of some adducts can actually be reduced by exposures 69 
to inhaled pollutants.  70 
McCreanor, et al. reported that walking for two hours along Oxford Street - a busy commercial road in central 71 
London, U.K., where traffic is restricted to diesel buses and taxis - was associated with significant reductions in 72 
lung function among asthmatics 21. In a more recent study, participants with COPD or IHD were compared to 73 
healthy controls to evaluate the impact of walking along Oxford Street on respiratory and cardiovascular functions 74 
in elderly participants with chronic diseases (referred to as “the Oxford Street Study II”) 22. Since oxidative stress 75 
contributes to COPD and IHD, we wished to determine whether Cys34 adductomics could differentiate global 76 
characteristics of the redox proteome (e.g. sulfoxidations and mixed disulfides) 17 between diseased and healthy 77 
subjects.  Likewise, we were curious as to whether adductomes were influenced by urban air pollution. To test 78 
these hypotheses, we obtained serum samples from nonsmoking participants and matched controls in the Oxford 79 
Street Study II and also residential levels of air pollutants that had been estimated from spatial models for each 80 
subject 22-25. After performing Cys34 adductomics with the serum, we compared adduct levels between healthy 81 
subjects and patients with COPD or IHD to find discriminating adducts and also investigated associations between 82 
adducts and levels of air pollutants.   83 
Materials and Methods  84 
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Serum samples and air-pollutant data. Archived serum samples, stored at -80oC, were obtained from 85 
nonsmoking subjects (either never smokers or ex-smokers for at least 12 months) in the Oxford Street Study II, 86 
namely healthy participants (n = 20, 10 males & 10 females) and participants with either COPD (n = 20, 9 males 87 
& 11 females) or IHD (n = 10, all males).  Subjects had been recruited with informed written consent under 88 
protocols approved by institutions who collaborated in Oxford Street II 22 .  Demographic characteristics, 89 
including age, smoking histories, lung function and medications are given in Table S1.  Two blood specimens 90 
were collected from each subject at the hospital laboratory: one at 8 a.m. prior to being exposed to air pollution 91 
for two hours while walking on Oxford Street and another collected at 8 a.m. on the following day. Annual average 92 
air concentrations of ambient air pollutants (PM2.5, NO2 & O3) at each residence were estimated from spatial 93 
models 25. Pollutant concentrations varied between 0.27-fold and 1.12-fold across subjects (PM2.5: 14.2-18.0 94 
µg/m3, median = 15.4 µg/m3; NO2: 23.6-50.1 µg/m
3, median = 36.2 µg/m3; O3: 37.5-51.7 µg/m
3, median = 43.5 95 
µg/m3).  96 
 Liquid chromatography-mass spectrometry. Digested serum was analyzed by nano-liquid-chromatography 97 
high-resolution mass spectrometry (nLC-HRMS) to detect Cys34 adducts of HSA, as described previously in 98 
detail 12. Briefly, samples containing approximately 0.1 mg of HSA (after methanol precipitation) were digested 99 
with trypsin using pressure cycling (Barocycler NEP2320, Pressure Biosciences Inc.) for 30 min at 37oC. One 100 
microliter of each tryptic digest was analyzed with a LTQ Orbitrap XL HRMS coupled to a Dionex Ultimate® 101 
3000 nanoflow LC system using a nano-electrospray-ionization source operated in positive-ion mode (Thermo 102 
Scientific, Sunnyvale, CA). Peptides were separated at a flow rate of 750 nL/min with a Dionex PepSwift 103 
monolithic nanoflow column (100-μm i.d. × 25 cm). Mass spectra were acquired over the range m/z = 750 to 1000 104 
using the Orbitrap mass analyzer.  In data-dependent mode, up to six triply charged precursor ions were selected 105 
from each MS1 scan and fragmented by collision-induced dissociation and analyzed in the linear ion trap (MS2). 106 
Sample processing and data acquisition. Adducts were located in the third largest (‘T3’) peptide of HSA, with 107 
sequence 21ALVLIAFAQYLQQC34PFEDHVK41.  Duplicate specimens were processed in 10 batches.  To adjust 108 
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for variation in the amount of HSA digested in individual serum samples, peak areas of T3 adducts were 109 
normalized by the corresponding peak area of the adjacent HSA tryptic peptide that we refer to as a 110 
“housekeeping” (HK) peptide (42LVNEVTEFAK51). The peak area ratio (PAR, adduct peak area/HK peptide 111 
peak area) was used for statistical analyses. The rationale for using PARs for quantitation and their extensive 112 
validation with reference T3 adducts were described previously 12.  Values below the limit of quantitation (LOQ) 113 
were imputed a PAR of LOQ/√2 = 2.87×10-5 where the LOQ was estimated as the mean PAR observed for the 114 
seven smallest abundances of all putative T3 peptides.  Added masses were calculated relative to the thiolate form 115 
of the T3 peptide (Cys34-S-).   116 
Statistical analyses. Statistical analyses were performed for each putative T3 adduct as described previously 12, 117 
20, using ln(PAR) as the dependent variable with SAS software for Windows (v. 9.4, SAS Institute, Cary, NC). 118 
Briefly, PARs were adjusted for batch effects, and subject-specific random effects were predicted from all 119 
replicate measurements using a linear mixed effects model (Proc MIXED of SAS).  These predicted random 120 
effects were used for statistical analyses.  First, Wilcoxon rank-sum exact tests (Proc NPAR1Way of SAS), were 121 
performed for T3 modifications with intraclass correlation coefficients (ICC) > 0.10 (n = 34), to determine 122 
whether adduct levels differed between COPD or IHD patients and healthy participants. Since males and females 123 
were available for COPD patients and healthy participants, the tests included both genders, whereas comparisons 124 
for IHD were performed for males only.  Significance for multiple comparisons was gauged with a Bonferroni-125 
corrected p-value = 0.00147.  Finally, multivariable linear regression analyses (Proc REG of SAS) were 126 
performed, using the batch-adjusted ln(PAR) as the dependent variable and participant group, gender, age and 127 
residential levels of PM2.5, NO2 & O3 as independent variables.  128 
Results 129 
Characterization of adducts. More than 7000 peaks were located as possible T3 modifications in the 208 nLC-130 
HRMS runs that were clustered into 83 adduct features.  Manual curation eliminated 44 features that were not 131 
present in sufficient numbers of subjects for statistical analysis.  This resulted in quantitation of 39 distinct T3-132 
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related adduct features (designated OS1 to OS39) as summarized in Table 1.  As anticipated, adduct levels were 133 
essentially identical in blood samples collected from the same subjects on two consecutive days, consistent with 134 
the 28-d residence time of HSA.  Over half of the features were annotated based on added masses, and MS2 135 
spectra indicated that some were T3 modifications at sites other than Cys34. Most of these peptides had previously 136 
been observed in our laboratory 12, 20, including truncations (OS1 and OS2), a labile T3 adduct that disassociated 137 
in the electrospray (OS3) 20, unmodified T3 (OS4), T3 methylation (OS7), Cys34 oxidation products (OS6, OS11 138 
& OS13), a likely product of reaction with either benzaldehyde or quinone methide (OS17) and 15 mixed Cys34 139 
disulfides (the largest class of modifications). Nine adduct features, including dehydrated and methylated forms 140 
of Cys34 sulfoxidation products (OS9, OS10 and OS12) and six unknown adducts had not been detected in our 141 
previous investigations. The MS1 scans, selected ion chromatograms and MS2 spectra of the 9 unique adducts 142 
from this study are presented in Figs. S1 and S2.  Estimated PARs ranged from 2.0×10-5 to 2.2×10-1, 143 
corresponding to approximate adduct concentrations of 0.048 to 646 pmol/mg HSA (Table 1).  Annotations of 10 144 
adducts (indicated in Table 1) were confirmed by comparisons with reference standards. 145 
Associations of adducts with disease status. Thirty four T3-related peptides, with ICC values greater than 0.10, 146 
were tested for differences between participant groups. As shown in Table 2, seven adducts potentially 147 
discriminated between COPD subjects and healthy participants (p-value < 0.05), notably two oxidation products 148 
(OS6 & OS11), S-GSH (OS32), a methylated oxidation product (OS12) and an unknown adduct (OS33).  An 149 
additional subset of seven adducts potentially discriminated between the IHD subjects and healthy participants, 150 
including the Cys34 oxidation-plus-methylation product (OS12).  Four of the associations were common to both 151 
COPD & IHD subjects (OS6, OS11, OS12 & OS33).  Interestingly, all but two of the detected associations (OS2 152 
& OS4 with COPD) reflected lower adduct levels in diseased subjects than healthy participants.  153 
Multivariate regression. Multivariate regression models were fitted for 34 adduct features, with results 154 
summarized in Table 3 for models having at least one covariate effect with a p-value <0.05. All seven of the 155 
univariate associations for COPD (Table 2) were replicated after controlling for age, gender, and residential air-156 
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pollutant concentrations of  PM2.5, NO2 and O3 and two additional associations were detected (OS17 and OS22).  157 
However, two of the 7 univariate associations with IHD (OS13 & OS17) did not replicate in the multivariate 158 
models and no additional associations with IHD were detected.  Although air pollution levels were highly 159 
correlated across residences, with correlation coefficients all greater than >0.90 (not shown), they appeared to 160 
differentially affect adduct levels. For example, increased levels of NO2 and O3 were associated with decreased 161 
Cys34 sulfonic acid levels (OS13), while PM2.5 appeared to have no effect on this adduct. On the other hand, 162 
increased PM2.5 concentrations were associated with decreased levels of unmodified T3 (OS4), whereas exposures 163 
to NO2 and O3 had no apparent effect on this feature.   164 
Discussion 165 
This is the first application of our adductomics methodology to investigate effects of respiratory and 166 
cardiovascular diseases and influences of ambient air pollution. We measured 39 Cys34 (and related) adducts in 167 
serum digests from 50 nonsmoking subjects in Oxford Street Study II, including 20 healthy participants, 20 with 168 
COPD and 10 with IHD. The Oxford Street Study II was designed to detect acute effects of urban air pollution 169 
(primarily diesel exhaust) during 2-h excursions of participants in a heavily polluted area of London, U.K22. Since 170 
HSA turns over with a residence time of 28 d, we recognized that our application of adductomics was unlikely to 171 
detect effects of 2-h exposures and, indeed, adduct levels were essentially unchanged on consecutive days, before 172 
and after the excursions on Oxford Street.  Rather, we focused on possible long-term effects of air pollutants as 173 
indicated by modeled exposures to PM2.5, NO2 and O3 at each subject’s residence.      174 
Multivariate linear regression models detected 18 significant associations with underlying diseases or pollutant 175 
exposures, 14 of which were in the negative direction (adducts levels decreased with the presence of disease or 176 
higher air pollutant concentrations, Table 3). Five of the seven Cys34 adducts that discriminated for COPD (p-177 
value < 0.05) were present at lower levels in COPD patients than in healthy subjects (Table 2), with ratios of 178 
COPD patients/healthy subjects ranging between 76% and 86% (median = 85%). The ratios of the 7 179 
discriminating adducts for IHD patients/healthy subjects ranged between 43% and 86% (median = 80%). Because 180 
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our serum samples were from a cross-sectional study, it is not clear whether the detected associations between 181 
adduct levels and disease status were related to possible causal factors or to effects of the diseases themselves 182 
(reverse causality).  183 
Four adducts were negatively associated with both COPD and IHD (three Cys34 oxidation products and the 184 
Cys34-GSH disulfide).  This is interesting because we had found similar negative associations of the Cys34 185 
oxidation products in smokers 12 and of the Cys34-GSH disulfide in women exposed to indoor combustion 186 
products 20 (Table 4). Since oxidative stress is a hallmark of COPD and cigarette smoking 10, it is perhaps 187 
surprising that production of Cys34 oxidation products would be diminished in COPD patients and smokers. 188 
However, these results are consistent with dysregulation of pathways related to redox control of Cys34 due to 189 
hypoxia, which is characteristic of both COPD 26-28 and IHD29-32 as well as chronic exposure to cigarette smoke 190 
33-36. Alternatively, differential rates of adduction could be related to structural and conformational specificities 191 
of reduced and oxidized forms of Cys34 37-38, to interactions with other influential HSA loci (e.g. His39 and Tyr84) 192 
39, and to nearby HSA binding of ligands such as fatty acids40-41. Reduced levels of Cys34-GSH in COPD & IHD 193 
patients are consistent with depletion of endogenous GSH by ROS as suggested by other avenues of research.  194 
For example, COPD patients had reduced concentrations of endogenous GSH in bronchoalveolar-lavage fluid 42 195 
and lower levels of glutamylcysteine ligase, a key enzyme in glutathione synthesis, in alveolar macrophages and 196 
the bronchial epithelium 43.   197 
  Although most of the detected associations were with disease status, suggesting that redox control was driven 198 
by the diseases, a few adducts were associated with residential concentrations of air pollutants that had been 199 
estimated from spatial models (Table 3). Inverse associations were observed between the Cys34 sulfonic acid 200 
(trioxidation product, OS13) and NO2 & O3 and between the unmodified T3 peptide (OS4) and PM2.5. This 201 
behavior could again reflect dysregulation of redox control or could result from other exposure-related phenomena, 202 
such as altered Cys34 adduction due to binding at other sites on the HSA molecule or to altered rates of HSA 203 
turnover 44.  The weak positive association of NO2 with the putative adduct of either benzaldehyde or quinone 204 
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methide is perplexing because both benzaldehyde and quinone methide are primarily products of nutrients and 205 
microbial metabolites 45-46 that should not be sensitive to air pollution.    206 
This was the first application of untargeted analyses to discover associations between adductomes and 207 
exposures to ambient air pollution.  A few such associations were detected despite rather small though exposure 208 
contrasts (pollutant concentrations varied between 0.27-fold and 1.12-fold across subjects).  It would be 209 
interesting to further investigate adductomes related to wide concentration ranges of ambient air pollutants, such 210 
as when subjects are stratified between inner cities and rural locations. Regarding possible seasonal effects, blood 211 
samples from this study were evenly distributed over the time period from December 2012 to March 2014. 212 
Multivariate regression models indicated that season had no significant effect on adduct levels when other 213 
covariates (gender, age & pollutant exposures) were included.        214 
The above findings demonstrate that Cys34 adductomics offers a data-driven avenue for studies of respiratory 215 
and cardiovascular diseases and their connections with air pollutants.  Despite small sample sizes, a variety of 216 
Cys34 modifications were associated with COPD, IHD and levels of air pollutants.  These associations provide 217 
evidence that Cys34 adductomics can discover HSA modifications that discriminate across populations based on 218 
disease status and levels of pollutant exposures.  By discovering unanticipated associations, Cys34 adductomics 219 
also highlights the value of untargeted analyses for generating hypotheses that can be pursued in subsequent 220 
investigations of the etiologies of respiratory and cardiovascular diseases.  For example, serum metabolomics of 221 
reduced and oxidized forms of glutathione could be performed to test hypotheses related to GSH depletion and 222 
redox control.  223 
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Table 1. Putative T3 peptides detected in serum from the Oxford Street subjects.  363 
Adduct 
Retentio
n Time 
(min) 
m/z, 3+, 
Observed 
ΔMass 
(ppm) 
PARd(x1000) 
(median) 
Conc. 
(pmol/mg 
HSA) 
Mass (Da) 
Added to T3 
(Cys34-S-) 
Elemental 
Composition Mass 
Added to Cys34-S- 
Putative Annotation 
OS1a,b 30.23 808.7320  0.066 0.196 -9.093  Not Cys34 adduct 
OS2 b 30.51 810.4536  0.126 0.365 -3.928  Not Cys34 adduct 
OS3 a,b 30.17 811.7620 3.27 1.821 5.252 -0.002 +H T3 labile adduct 
OS4 a,b 30.61 811.7611 -2.17 9.940 28.726 0.000 +H Unmodified T3 
OS5 a,b 32.15 811.4257 0.002 3.068 9.143 2431.248 + C114H172N27O30S T3 dimer 
OS6 a,b,e 29.68 816.4197 -0.723 1.107 3.174 13.971 -H2, +O Cys34-Gln crosslink (monooxidation) 
OS7 a,b 31.00 816.4319 0.81 0.225 0.652 15.0262 +CH3 Methylation (not Cys34)c 
OS8 b 30.39 820.0921 -1.207 0.064 0.187 25.9952 +CN S-Addition of cyanide 
OS9 30.10 821.0916 -0.743 0.059 0.171 28.9932 + CHO Dehydrated form of OS12 
OS10 30.29 821.7513 -0.706 0.020 0.058 30.9722 -H2, +O2 Dehydrated form of OS13c 
OS11 a,b,e 29.68 822.4233 -0.851 1.415 3.976 32.9882 +HO2 Cys34 sulfinic acid (dioxidation) 
OS12 30.11 827.0946 0.09 0.053 0.149 47.0022 OS11+CH2 
Cys34 sulfinic acid plus methylation 
(not Cys34) 
OS13 a,b,e 29.93 827.7550 -0.870 0.200 0.595 48.9832 +HO3 Cys34 sulfonic acid (trioxidation) 
OS14 a 29.63 841.0986 -0.725 0.129 0.375 89.0142 +C3H5O3 
S-Addition of pyruvate or malonate 
semialdehyde 
OS15 a,b 30.41 841.7529 -1.224 0.496 1.422 90.9772 +C2H3O2S S-Addition of mercaptoacetic acid 
OS16 a,b,e 29.59 845.4246 -0.804 0.727 2.126 101.9922 +C3H4NOS S-Cys (−H2O) 
OS17 a,b 31.58 847.1082 -1.818 0.059 0.175 107.0432 +C7H7O 
S-Addition of benzaldehyde or 
quinone methide 
OS18 a,b,e 28.71 851.4297 -2.666 220.280 645.764 120.0072 +C3H6NO2S S-Cys 
OS19 a,b 28.72 851.7571 -2.007 0.790 2.301 120.9972 +C3H5O3S S-Cys(NH2 → OH) c 
OS20 a,b,e 29.19 856.1004 -1.262 14.856 43.119 134.0202 +C4H8NO2S S-hCys 
OS21 a,b,e 28.92 856.1011 -2.161 11.018 32.66 134.0222 +C4H8NO2S S-hCys 
OS22  29.02 857.0876  0.123 0.354 136.9812  Unknown 
OS23 a,b 28.71 858.7534 1.572 0.529 1.542 141.9792 OS18+Na Na adduct of S-Cys 
OS24 a 29.27 860.7717 -0.662 0.333 1.015 148.0342 OS21+CH2 
S-hCys, plus methylation 
(not Cys34) 
OS25 a,b 29.33 864.4318 -0.949 0.143 0.418 159.0142 +C5H7N2O2S S-CysGly (−H2O) 
OS26 a,b 29.71 865.4312 -0.277 0.049 0.141 162.0122 +C5H8NO3S S-(N-acetyl)Cys 
OS27 a,b,e 28.42 870.4369 -2.677 25.414 75.15 177.0292 +C5H9N2O3S S-CysGly 
OS28 a 28.63 875.1062 0.251 0.896 2.663 191.0372 OS27+CH2 
S-CysGly, plus methylation 
(not Cys34) 
OS29 a 27.29 894.1270  0.095 0.272 248.0992  Unknown 
OS30 a,b,e 28.95 894.4429 -1.442 2.972 8.635 249.0472 +C8H13N2O5S S-γ-GluCys 
OS31 29.30 899.1140  0.078 0.222 263.0612  Unknown 
OS32 a,b,e 28.80 913.4498 -1.171 2.551 7.109 306.0682 +C10H16N3O6S S-GSH 
OS33 29.18 918.1222  0.092 0.245 320.0852  Unknown 
OS34 27.11 927.1408  0.075 0.224 347.1412  Unknown 
OS35 32.21 928.7842  0.130 0.379 352.0712  Unknownc 
OS36 a 27.68 931.8218  0.097 0.277 361.1842  Unknown 
OS37 a 27.67 965.4928  5.581 15.639 462.1972  Unknown 
OS38 28.07 970.1643  0.260 0.756 476.2112  Unknownc 
OS39 a  29.13 976.8207  0.060 0.175 496.1812  Unknown 
a Also observed by Lu et al. 20  364 
b Also observed by Grigoryan et al. 12 365 
c Adduct with intraclass correlation coefficient (ICC) < 10% 366 
d PAR, peak area ratio, adduct peak area/housekeeping peptide peak area 367 
e Identity confirmed with reference standard 368 
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Table 2.  Mean peak-area ratios (PAR) for adducts with at least one significant difference between either COPD or IHD 375 
patients and healthy subjects (Wilcoxon test, p-value ≤ 0.05). 376 
Adduct 
Putative 
Annotation 
Healthy Subjects (n=20) COPD Subjects (n=20) IHD Subjects (n=10) 
    PAR(x1000) PAR(x1000) p-Value PAR(x1000) p-Value 
OS2 Not Cys34 adduct  0.119 0.148 0.01674 0.120 0.91396 
OS4 Unmodified T3 9.470 10.620 0.04595 9.950 0.68112 
OS6 
Cys34-Gln crosslink 
(monooxidation) 
1.209 1.044 0.00427 1.037 0.01458 
OS11 
Cys34 Sulfinic acid 
(dioxidation) 
1.536 1.302 0.00353 1.292 0.01666 
OS12 
Cys34 sulfinic acid 
plus methylation 
0.058 0.050 0.01674 0.045 0.00026* 
OS13 Cys34 Sulfonic acid 0.222 0.214 0.46117 0.184 0.01897 
OS17 
Benzaldehyde or 
quinone methide  
0.109 0.067 0.12735 0.047 0.04783 
OS23 Na adduct of S-Cys 0.581 0.543 0.32726 0.465 0.01897 
OS32 S-GSH 2.917 2.271 0.00093* 2.363 0.13073 
OS33 Unknown 0.104 0.079 0.00159 0.080 0.04903 
*Significant association after Bonferroni adjustment (p-value < 0.00147) 377 
  378 
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Table 3. Results of multivariate linear regression models. p-values and directions of associations are shown for the 380 
following covariates: COPD (COPD = 1; healthy subject = 0), IHD (IHD = 1; healthy subject = 0), gender (male = 1, female = 381 
0). Results are only shown for models having at least one significant covariate effect (p-value < 0.05). Arrows indicate 382 
associations that either increased (↑) or decreased (↓) with the predictor variable. 383 
Adduct 
Putative 
Annotation 
COPD IHD Gender Age NO2 O3 PM2.5 Adj. R2 
OS2 Not Cys34 adduct 0.0323 (↑)       0.056 
OS3 T3 labile adduct   0.022 (↓)     0.200 
OS4 Unmodified T3 0.0284 (↑)      0.0183 (↓) 0.166 
OS6 
Cys34-Gln crosslink 
(monooxidation) 
0.0302 (↓) 0.0717 (↓)  0.0495 (↓)    0.313 
OS11 
Cys34-Sulfinic acid 
(dioxidation) 
0.0378 (↓) 0.0271 (↓)      0.292 
OS12 
Cys34 sulfinic acid 
plus methylation 
0.0447 (↓) 0.0078 (↓)      
0.238 
OS13 Cys34 Sulfonic acid     0.0477 (↓) 0.0426 (↓)  0.104 
OS17 
Benzaldehyde or 
quinone methide 
0.0247 (↓)    0.0174 (↑)   
0.199 
OS22 Unknown 0.0317 (↑)  0.026 (↑)     0.187 
OS32 S-GSH 0.0015 (↓) 0.0097(↓)      0.193 
OS33 Unknown 0.0017 (↓) 0.0041 (↓)      0.199 
  384 
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Table 4. Comparison of adduct associations from the current study with those of the same adducts in two previous 391 
studies.  Associations with the indicated predictor variable at a p-value < 0.05 were obtained from multivariate linear 392 
regression models after controlling for covariates.  Each arrow indicates the direction of the association with the 393 
predictor variable. (Boldface arrows indicate adducts detected in both the current study and a previous study).  394 
Adduct Annotation Current Studya 
Smoky Coal 
Ref. 20,b 
Smoking 
Ref. 12,c 
  COPD IHD NO2 O3 PM2.5 
  
OS2 Not Cys34 adduct ↑     
 
↓ 
OS4 Unmodified T3 ↑    ↓ 
  
OS6 Cys34-Gln crosslink (monooxidation) ↓ ↓    
 
↓ 
OS11 Cys34 sulfinic acid (dioxidation) ↓ ↓    
 
↓ 
OS12 Cys34 sulfinic acid, plus methylation ↓ ↓    
  
OS13 Cys34 sulfonic acid (trioxidation)   ↓ ↓  
 
↓ 
OS17 Benzaldehyde or quinone methide ↓  ↑   
  
OS22 Unknown ↑     
 
↓ 
OS32 S-GSH ↓ ↓    ↓ 
 
OS33 Unknown ↓ ↓    
  
a Covariates were age and gender. 395 
b Covariates were age and log-transformed levels of benzo(a)pyrene.  396 
c Covariates were race, gender, bmi, and consumption of animal fat and vegetable fat. 397 
 398 
 399 
